Amgen Announces Positive Phase 2 Results In A Rare Form Of Blood Cancer
July 16, 2015 at 20:34 PM EDT
Amgen reports positive phase 2 data for Blincyto as a cancer treatment, in addition to previously approved applications. The stock climbed briefly to $165 post-announcement.
